• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病基金会《慢性阻塞性肺疾病袖珍咨询指南》2017年更新版

The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.

作者信息

Yawn Barbara Bp, Thomashaw Byron, Mannino David M, Han MeiLan K, Kalhan Ravi, Rennard Stephen, Cerrata Scott, Crapo James D, Wise Robert

机构信息

Department of Family and Community Health, University of Minnesota School of Medicine, Minneapolis.

Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York.

出版信息

Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):177-185. doi: 10.15326/jcopdf.4.3.2017.0136.

DOI:10.15326/jcopdf.4.3.2017.0136
PMID:28848929
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5556909/
Abstract

The COPD Foundation Pocket Consultant Guide (PCG) was first released in 2007 as a practice tool for use at point of service for clinicians, especially primary care clinicians diagnosing and treating patients with chronic obstructive pulmonary disease (COPD). Over the years, the PCG has been supplemented with a mobile app that presents the tool in an online smart phone accessible version that also allows the clinician to enter patient specific data for guidance to next steps of diagnosis or management. In November 2016, a new update of the PCG was released that incorporates a flow diagram for stepped care that includes the newest recommendation for diagnosis, assessment and treatment; including the broad use of dual bronchodilator therapy and consideration of asthma COPD overlap syndrome (ACOS). The current controversy regarding when to add inhaled corticosteroids (ICSs) is addressed to support clinical decision making. The PCG comes in 2 versions, one with generic names for COPD drugs available in the United States and one with trade names for those drugs. The update continues to recommend spirometry for those at highest risk, also emphasizing the need to assess symptoms, exacerbation risks and comorbidity before selecting appropriate non-pharmacological as well as pharmacological therapy. The tool is designed to facilitate COPD management in daily practice.

摘要

慢性阻塞性肺疾病基金会袖珍咨询指南(PCG)于2007年首次发布,作为一种实践工具供临床医生,尤其是诊断和治疗慢性阻塞性肺疾病(COPD)患者的初级保健临床医生在服务点使用。多年来,PCG已通过一款移动应用程序进行补充,该应用程序以在线智能手机可访问版本呈现该工具,还允许临床医生输入患者特定数据以指导诊断或管理的下一步操作。2016年11月,发布了PCG的新更新版本,其中纳入了阶梯式治疗流程图,包括诊断、评估和治疗的最新建议;包括广泛使用双联支气管扩张剂治疗以及考虑哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)。解决了当前关于何时添加吸入性糖皮质激素(ICS)的争议,以支持临床决策。PCG有两个版本,一个版本使用美国可用的COPD药物通用名,另一个版本使用这些药物的商品名。该更新继续推荐对高危人群进行肺功能测定,同时强调在选择适当的非药物以及药物治疗之前,需要评估症状、加重风险和合并症。该工具旨在促进日常实践中的COPD管理。

相似文献

1
The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.慢性阻塞性肺疾病基金会《慢性阻塞性肺疾病袖珍咨询指南》2017年更新版
Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):177-185. doi: 10.15326/jcopdf.4.3.2017.0136.
2
Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation.推出全新慢性阻塞性肺疾病袖珍咨询指南应用程序:数字方法能否改善护理?慢性阻塞性肺疾病基金会声明。
Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):210-220. doi: 10.15326/jcopdf.6.3.2018.0167.
3
COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.COPD-X 澳大利亚和新西兰慢性阻塞性肺疾病诊断和管理指南:2017 年更新版。
Med J Aust. 2017 Nov 20;207(10):436-442. doi: 10.5694/mja17.00686.
4
Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.慢性阻塞性肺疾病 - 稳定期疾病的诊断和管理;基于临床表型的可治疗特征概念,采用个体化护理方法。捷克肺病和结核学会立场文件。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):325-356. doi: 10.5507/bp.2020.056.
5
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.慢性阻塞性肺疾病稳定期的诊断与管理:美国医师学会、美国胸科学会、美国胸科学会和欧洲呼吸学会的临床实践指南更新。
Ann Intern Med. 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008.
6
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
7
Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.低剂量茶碱口服联合吸入皮质激素治疗慢性阻塞性肺疾病且有加重高风险的患者:一项 RCT 研究。
Health Technol Assess. 2019 Jul;23(37):1-146. doi: 10.3310/hta23370.
8
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)的药理学管理。
Expert Opin Pharmacother. 2020 Feb;21(2):213-231. doi: 10.1080/14656566.2019.1701656.
9
Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.慢性阻塞性肺疾病(COPD)队列中哮喘-COPD重叠综合征患者的治疗趋势:一项真实世界调查的结果
Int J Chron Obstruct Pulmon Dis. 2017 Jun 15;12:1753-1763. doi: 10.2147/COPD.S136314. eCollection 2017.
10
Overuse of long-acting β-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.慢性阻塞性肺疾病患者长效β受体激动剂/吸入性糖皮质激素的过度使用:是时候重新思考处方模式了。
Postgrad Med. 2023 Nov;135(8):784-802. doi: 10.1080/00325481.2023.2284650. Epub 2024 Jan 10.

引用本文的文献

1
COPD Phenotyping.慢性阻塞性肺疾病表型。
Respir Care. 2023 Jul;68(7):871-880. doi: 10.4187/respcare.11035.
2
A Model to Predict Residual Volume from Forced Spirometry Measurements in Chronic Obstructive Pulmonary Disease.一种通过慢性阻塞性肺疾病的用力肺活量测量来预测残气量的模型。
Chronic Obstr Pulm Dis. 2023 Jan 25;10(1):55-63. doi: 10.15326/jcopdf.2022.0354.
3
Variation in Demographic and Clinical Characteristics of Patients with COPD Receiving Care in US Primary Care: Data from the Advancing the Patient EXperience (APEX) in COPD Registry.美国初级保健中接受治疗的慢性阻塞性肺疾病(COPD)患者的人口统计学和临床特征差异:来自慢性阻塞性肺疾病患者体验提升(APEX)注册研究的数据。
Pragmat Obs Res. 2022 Apr 29;13:17-31. doi: 10.2147/POR.S342736. eCollection 2022.
4
Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者单吸入器三联疗法新使用者的患者及临床人口统计学特征
Pulm Ther. 2022 Jun;8(2):195-208. doi: 10.1007/s41030-022-00189-6. Epub 2022 Apr 25.
5
GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting.实践中的 GOLD:初级保健环境中的慢性阻塞性肺疾病治疗和管理。
Int J Chron Obstruct Pulmon Dis. 2021 Feb 12;16:289-299. doi: 10.2147/COPD.S222664. eCollection 2021.
6
A Simplified Algorithm for the Diagnosis, Treatment, and Management of COPD in Routine Primary Care Practice.慢性阻塞性肺疾病在常规初级保健实践中的诊断、治疗和管理的简化算法。
Int J Chron Obstruct Pulmon Dis. 2020 Dec 16;15:3347-3355. doi: 10.2147/COPD.S281422. eCollection 2020.
7
Design of the Redefining Therapy in Early COPD Study.慢性阻塞性肺疾病早期重新定义治疗研究的设计
Chronic Obstr Pulm Dis. 2020 Oct;7(4):382-389. doi: 10.15326/jcopdf.7.4.2020.0157.
8
Sarcopenia and low muscle radiodensity associate with impaired FEV in allogeneic haematopoietic stem cell transplant recipients.肌肉减少症和低肌肉放射密度与异基因造血干细胞移植受者的 FEV 受损相关。
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1570-1579. doi: 10.1002/jcsm.12604. Epub 2020 Jul 29.
9
Comparison of Compliance Rates and Treatment Efficiency in Home-Based with Hospital-Based Pulmonary Rehabilitation in COPD.慢性阻塞性肺疾病(COPD)患者居家与住院肺康复的依从率及治疗效果比较
Turk Thorac J. 2019 Jul 1;20(3):192-197. doi: 10.5152/TurkThoracJ.2019.18060. Print 2019 Jul.
10
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study.慢性阻塞性肺疾病患者短期临床显著恶化的长期成本和效用后果:来自 TORCH 研究的结果。
Int J Chron Obstruct Pulmon Dis. 2019 May 3;14:939-951. doi: 10.2147/COPD.S188898. eCollection 2019.

本文引用的文献

1
Exacerbations in the pre- and post-COPD diagnosis periods.慢性阻塞性肺疾病(COPD)诊断前后的病情加重情况。
Pragmat Obs Res. 2013 Apr 30;4:1-6. doi: 10.2147/POR.S41778. eCollection 2013.
2
Deaths: Final Data for 2014.死亡:2014年最终数据。
Natl Vital Stat Rep. 2016 Jun;65(4):1-122.
3
Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.肺功能正常的吸烟者症状的临床意义
N Engl J Med. 2016 May 12;374(19):1811-21. doi: 10.1056/NEJMoa1505971.
4
Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis.长效β-激动剂/长效毒蕈碱拮抗剂联合治疗 COPD 的疗效和安全性:一项网络荟萃分析。
Thorax. 2016 Jan;71(1):15-25. doi: 10.1136/thoraxjnl-2014-206732. Epub 2015 Oct 21.
5
The Asthma-COPD Overlap Syndrome.哮喘-慢阻肺重叠综合征。
N Engl J Med. 2015 Sep 24;373(13):1241-9. doi: 10.1056/NEJMra1411863.
6
Clinical and Radiologic Disease in Smokers With Normal Spirometry.肺功能正常的吸烟者的临床和放射学疾病
JAMA Intern Med. 2015 Sep;175(9):1539-49. doi: 10.1001/jamainternmed.2015.2735.
7
Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis.为慢性阻塞性肺疾病患者个性化定制年度肺癌筛查:一项决策分析。
Cancer. 2015 May 15;121(10):1556-62. doi: 10.1002/cncr.29225. Epub 2015 Feb 3.
8
Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.慢性阻塞性肺疾病患者的肺癌。慢性阻塞性肺疾病肺癌筛查评分的制定与验证。
Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91. doi: 10.1164/rccm.201407-1210OC.
9
Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation.介绍 COPD 基金会 COPD 诊断和管理指南,这是 COPD 基金会的建议。
COPD. 2013 Jun;10(3):378-89. doi: 10.3109/15412555.2013.801309.
10
COPD surveillance--United States, 1999-2011.慢性阻塞性肺疾病监测——美国,1999-2011 年。
Chest. 2013 Jul;144(1):284-305. doi: 10.1378/chest.13-0809.